Read this topic

Cannabis use and psychosis matters because the risk of developing psychosis is not fixed, it rises with the dose, the potencyHow small a dose of a drug is needed to produce a given effect.Read more → of the cannabis used, and how early in life use begins. It is understood as a dose-related association: heavier use, higher-THC (tetrahydrocannabinol, the main psychoactive component of cannabis) products, and earlier age of first use each independently raise the risk of psychosis. For example, imagine two teenagers who both use cannabis: one uses low-potency cannabis occasionally, the other uses high-potency cannabis daily from age fourteen. In practice, the second teenager carries a substantially higher psychosis risk because of both potency and early onset.

THC (tetrahydrocannabinol) is the component most strongly linked to psychosis risk, whereas CBD (cannabidiol, a non-intoxicating cannabis component) may actually have some protective or antipsychotic properties. High-potencyHow small a dose of a drug is needed to produce a given effect.Read more → cannabis, sometimes called skunk, contains a much higher ratio of THC to CBD than traditional herbal cannabis, which is why potency matters as much as frequency. Amotivational syndrome, apathy, reduced drive, and declining performance at work or school with chronic heavy use, is a separate recognised complication distinct from psychosis. Say a heavy long-term cannabis user has not developed psychosis but has gradually dropped out of college and lost interest in his usual hobbies. In practice, this pattern points to amotivational syndrome rather than a psychotic illness, though both need addressing.

• At which receptor does tetrahydrocannabinol act to produce its psychoactive effects?
• How does cannabidiol differ from tetrahydrocannabinol in its psychiatric effects?
• A daily cannabis user has recurrent severe vomiting that only settles when he takes long hot showers. What is the diagnosis?

• Primary schizophrenia, can arise without any substance use, unlike cannabis-associated psychosis, which follows a pattern of heavy or early cannabis use.
• Amotivational syndrome, apathy and reduced drive from chronic heavy use, rather than the delusionsA fixed false belief, held with total conviction, that is not shared by the person's culture and is not changed by evidence against it.Read more → and hallucinationsSeeing, hearing, or otherwise sensing things that are not really there.Read more → that define psychosis.
• Low-potency, low-THC cannabis, carries comparatively lower psychosis risk, unlike high-potencyHow small a dose of a drug is needed to produce a given effect.Read more →, high-THC products such as skunk.
• CBD (cannabidiol), may have protective or antipsychotic properties, whereas THC is the component driving the psychosis association.

• CB2 receptors sit mainly on immune cells and are not responsible for the psychoactive effect.
• Mu opioid receptors mediate opioid effects rather than cannabinoid ones.
• 5-HT2AA serotonin receptor subtype that many antipsychotic drugs block, thought to help their antidepressant and antipsychotic effect.Read more → agonism describes classical hallucinogens such as LSD.
• Cannabidiol is not associated with rapid dependence.
• Inhibiting alcohol metabolism describes disulfiram, an unrelated drug.

• Extract the defining phenomenology, duration, severity and functional-impact clues.
• Match the pattern to the most specific diagnostic or assessment construct.
• Actively test the closest look-alike against the missing or contradictory clue.
• Choose the precise term rather than a broader category that is merely compatible.